Previous studies have shown that neutralizing CXCR2 can inhibit neutrophil-mediated colitis [30]; furthermore, genetic knockout of the CXCR2 gene is capable of inhibiting the formation of primary colon cancer in mice [31]. This evidence concerns the gene CXCR2 and colonic neoplasm.